Morton Toe and Neuromuscular Performance (NCT07588048) | Clinical Trial Compass
CompletedNot Applicable
Morton Toe and Neuromuscular Performance
Turkey (Türkiye)47 participantsStarted 2026-01-10
Plain-language summary
This cross-sectional observational study investigated whether female football players with Morton toe morphology differ from those with normal foot morphology in neuromuscular contractile properties and kinetic performance characteristics. Morton toe is a congenital foot variation in which the second toe is longer than the first. A total of 47 female football players were classified into two groups based on bilateral foot morphology: Morton foot group (n = 24) and normal foot group (n = 23). Neuromuscular properties of the dominant vastus lateralis muscle were assessed using tensiomyography, and kinetic performance was evaluated through a 40-cm drop jump test on dual force plates. The primary outcomes were contraction time (Tc) and reactive strength index (RSI). Secondary outcomes included relaxation time, delay time, sustain time, maximal displacement, jump height, peak power normalized to body mass, and landing net peak force normalized to body mass. Multiple linear regression models adjusted for age, body mass index, and mean arch index were used to evaluate whether group differences were independent of potential confounders. This study aimed to determine whether Morton toe morphology is associated with distinct neuromuscular and kinetic performance profiles in female athletes.
Who can participate
Age range
18 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Active female football players with a valid sports license for the current season
* Regular participation in training and competitive matches
* Bilateral Morton toe morphology (Δ ≤ -0.30 mm on both feet) or bilateral normal foot morphology (Δ \> +0.30 mm on both feet)
* Body mass index between 18.5 and 29.9 kg/m²
* Bilateral arch index between 14% and 29%
* Voluntary participation with written informed consent
Exclusion Criteria:
* Serious lower-extremity musculoskeletal injury within the past 12 months
* Neurological or orthopedic disease affecting measurement procedures
* Current use of pharmacological products affecting performance
* Acute pain, injury, or illness on the measurement day
* Menstruation on the measurement day (self-reported)
* Inconsistent bilateral foot morphology classification between feet
* Bilateral arch index below 14% (high arch) or above 29% (low arch)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.